We analyzed 217 patients with KMT2A-rearranged AML in two large sequential randomized trials. Those randomized to FLAG-Ida had markedly lower rates of relapse than other chemotherapy regimens. Molecular MRD assessment after cycle two was strongly prognostic for relapse and death. AML17 ISRCTN55675535 AML19 ISRCTN78449203

Subjects:
Myeloid Neoplasia
This content is only available as a PDF.
Copyright © 2025 American Society of Hematology
2025

Article PDF first page preview

First page of Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML
You do not currently have access to this content.
Sign in via your Institution